Recent structure-guided drug design efforts have optimized NAMPT inhibitor payloads to include suitable linker attachment sites, enabling stable conjugation to antibodies targeting various tumor antigens such as HER2, C4.4a, and B7H3 [134]. The gene discussed is ERBB2; the disease is neoplasm.